Recent advancements in prostate cancer treatment have introduced promising experimental therapies aimed at shrinking advanced tumors, particularly in cases where traditional treatments have become ineffective. One such development is the drug NXP800, which has demonstrated effectiveness in laboratory trials at the Institute of Cancer Research. This experimental medicine offers hope for patients with treatment-resistant prostate cancer, as it has shown potential in reducing tumor size.
In addition to NXP800, other innovative approaches are being explored. For instance, Vir Biotechnology has reported promising results with two experimental cancer treatments known as T-cell engagers. These therapies work by directing the immune system’s T cells to attack specific proteins associated with prostate cancer cells, leading to tumor shrinkage and decreased prostate-specific antigen (PSA) levels in patients with metastatic castration-resistant prostate cancer. Click for More Details
